Join to view full profile
2020 Santa Monica BlvdSte 600Santa Monica, CA 90404
Phone+1 310-633-8400
Fax+1 310-633-8419
Dr. Goldman is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
University of California (San Francisco)Residency, Internal Medicine, 2001 - 2004
Stanford University School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2003 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
- A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
- Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Start of enrollment: 2013 Nov 01
Publications & Presentations
PubMed
- Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer.Sara Sakowitz, Haley I Tupper, Lawrence N Benjamin, Scott Oh, Tao He
Chest. 2026-04-01 - 1 citationsTNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang, Ayushi S Patel, Ke Geng
Cancer Research. 2025-10-15 - 7 citationsUpdated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.Gregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, Ibiayi Dagogo-Jack, Raymond Esper
Journal of Thoracic Oncology. 2025-10-01
Lectures
- A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Improved Outcomes Reported with Second-Line Regimen of Ivonescimab Plus Chemotherapy in NSCLCOctober 8th, 2025- Dr Eric K. Singhi’s Top 5 Studies from WCLC 2025: A Thoracic Oncologist’s PerspectiveSeptember 22nd, 2025
- Ivonescimab Delays Lung Cancer Progression in EGFR-Mutated DiseaseSeptember 9th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
